NCT04737850View on ClinicalTrials.gov

Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

June 17, 2025

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Hetrombopag

Thrombopoietin receptor agonist

DRUG

Placebo

Placebo with no active pharmaceutical ingredient

Trial Locations (1)

100032

Beijing children's hospital .Capital medical university, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04737850 - Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter